European Journal of Surgical Oncology
Volume 35, Issue 12 , Pages 1257-1260, December 2009

The significance of immunohistochemistry positivity in sentinel nodes which are negative on haematoxylin and eosin in breast cancer

  • S. Mac Giobuin

      Affiliations

    • Departments of Breast and Endocrine Surgery, St Vincents University Hospital, Elm Park, Dublin 4, Ireland
    • Corresponding Author InformationCorresponding author. Tel.: +353 (1) 2094925; fax: +353 (1) 2693479.
  • ,
  • D.O. Kavanagh

      Affiliations

    • Departments of Breast and Endocrine Surgery, St Vincents University Hospital, Elm Park, Dublin 4, Ireland
  • ,
  • E. Myers

      Affiliations

    • Departments of Breast and Endocrine Surgery, St Vincents University Hospital, Elm Park, Dublin 4, Ireland
  • ,
  • A.O. Doherty

      Affiliations

    • Department of Radiology, St Vincents University Hospital, Elm Park, Dublin 4, Ireland
  • ,
  • C.M. Quinn

      Affiliations

    • Department of Histopathology, St Vincents University Hospital, Elm Park, Dublin 4, Ireland
  • ,
  • T. Crotty

      Affiliations

    • Department of Histopathology, St Vincents University Hospital, Elm Park, Dublin 4, Ireland
  • ,
  • D. Evoy

      Affiliations

    • Departments of Breast and Endocrine Surgery, St Vincents University Hospital, Elm Park, Dublin 4, Ireland
  • ,
  • E. McDermott

      Affiliations

    • Departments of Breast and Endocrine Surgery, St Vincents University Hospital, Elm Park, Dublin 4, Ireland

Accepted 1 April 2009.

Abstract 

Introduction

Sentinel lymph node (SLN) biopsy allows a more detailed examination of a smaller number of lymph nodes in patients with clinically node negative breast cancer. Immunohistochemistry detects small tumour burden not routinely seen on haematoxylin and eosin (H&E). The significance of such findings remains to be fully elucidated.

Aim

To assess the axillary disease burden of patients in whom the sentinel lymph node biopsy was positive on immunohistochemistry and negative on H and E.

Methods

An analysis of patients who underwent SLN mapping for breast cancer at St Vincent's University Hospital from January 1st, 2000 to December 31st, 2006 was conducted. All SLNs were assessed by serial H&E and IHC sections. Patients with micrometastases (0.2–2mm) underwent a completion axillary lymph node dissections (CLND). Patients with ITC (<0.2mm) were individually discussed and a CLND was performed selectively based on additional clinicopathological criteria and patient preference. Analysis of the additional nodes from CLND was performed. Patients were followed for a median of 27 months (range 12–72 months).

Results

1076 patients who underwent SLN were included for analysis. 211 (20%) had a positive SLN biopsy using H&E. Forty-nine patients (5%) had a negative SLN on H&E which was positive on IHC. Of these, 15 had micrometastases and underwent a CLND. Two had further axillary nodal disease. ITC were found in the remaining 34 patients. Sixteen of these patients underwent a CLND. Five of this group had further nodal disease.

Conclusion

Micrometastases and isolated tumour cells, detected only by immunohistochemical analysis of sentinel lymph nodes, are associated with further positive nodes in the axilla in up to 15% of patients. This upstaging of disease may impact upon patient outcome.

Keywords: Sentinel node biopsy, Breast cancer, Immunohistochemistry, Lymph node, Metastasis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0748-7983(09)00118-8

doi:10.1016/j.ejso.2009.04.004

European Journal of Surgical Oncology
Volume 35, Issue 12 , Pages 1257-1260, December 2009